Molecular detection of CF lung pathogens: Current status and future potential

Journal of Cystic Fibrosis

Volumn 12, Issue 3, 2013, Pages 194-205

  Pattison, Sally H ^a,b   Rogers, Geraint B ^c   Crockard, Martin ^d   Elborn, J Stuart ^a,b   Tunney, Michael M ^a  

^a QUEEN'S UNIVERSITY BELFAST   (United Kingdom)

^b QUEEN'S UNIVERSITY BELFAST   (United Kingdom)

^c KING'S COLLEGE LONDON   (United Kingdom)

^d Randox Laboratories Ltd   (United Kingdom)

Author keywords

Detection; Identification; Microbiology; Molecular; Pathogen

Indexed keywords

ANTIBIOTIC SENSITIVITY; BACTERIAL STRAIN; BACTERIUM CULTURE; BACTERIUM DETECTION; BACTERIUM IDENTIFICATION; CLINICAL PRACTICE; CYSTIC FIBROSIS; DISEASE ASSOCIATION; HUMAN; IN VITRO STUDY; LUNG INFECTION; MICROBIAL DIVERSITY; MICROBIAL IDENTIFICATION; MICROBIOLOGY; MOLECULAR DIAGNOSIS; NONHUMAN; REVIEW;

CYSTIC FIBROSIS; FORECASTING; HUMANS; LUNG; MOLECULAR DIAGNOSTIC TECHNIQUES;

EID: 84876975299     PISSN: 15691993     EISSN: 18735010     Source Type: Journal    
DOI: 10.1016/j.jcf.2013.01.007     Document Type: Review

References (84)

1. Cystic Fibrosis Foundation Patient Registry: 2007 annual data report 2008.
2. Taccetti G., Campana S., Festini F., Mascherini M., Döring G. Early eradication therapy against Pseudomonas aeruginosa in cystic fibrosis patients. Eur Respir J 2005, 26(3):458-461.
3. Lillquist Y.P., Cho E., Davidson A.G.F. Economic effects of an eradication protocol for first appearance of Pseudomonas aeruginosa in cystic fibrosis patients: 1995 vs. 2009. J Cyst Fibros 2011, 10(3):175-180. [5].
4. Mayer-Hamblett N., Kronmal R.A., Gibson R.L., Rosenfeld M., Retsch-Bogart G., Treggiari M.M., et al. Initial Pseudomonas aeruginosa treatment failure is associated with exacerbations in cystic fibrosis. Pediatr Pulmonol 2012, 47(2):125-134.
5. Cystic Fibrosis Trust Standards of Care Committee Standards for the clinical care of children and adults with cystic fibrosis in the UK 2011.
6. Kerem E., Conway S., Elborn S., Heijerman H. Standards of care for patients with cystic fibrosis: a European consensus. J Cyst Fibros 2005, 4(1):7-26.
7. Cystic Fibrosis Foundation Patient Registry: 2010 annual data report 2011.
8. Flume P.A., Mogayzel P.J., Robinson K.A., Goss C.H., Rosenblatt R.L., Kuhn R.J., et al. Cystic fibrosis pulmonary guidelines: treatment of pulmonary exacerbations. Am J Respir Crit Care Med 2009 November 01, 180(9):802-808.
9. UK Cystic Fibrosis Trust Working Group Antibiotic treatment for cystic fibrosis - third edition 2009.
10. Thomassen M.J., Demko C.A., Doershuk C.F. Cystic fibrosis: a review of pulmonary infections and interventions. Pediatr Pulmonol 1987, 3(5):334-351.
11. Zemanick E.T., Wagner B.D., Harris J.K., Wagener J.S., Accurso F.J., Sagel S.D. Pulmonary exacerbations in cystic fibrosis with negative bacterial cultures. Pediatr Pulmonol 2010, 45(6):569-577.
12. Tunney M.M., Field T.R., Moriarty T.F., Patrick S., Doering G., Muhlebach M.S., et al. Detection of anaerobic bacteria in high numbers in sputum from patients with cystic fibrosis. Am J Respir Crit Care Med 2008, 177(9):995-1001.
13. Tunney M.M., Klem E.R., Fodor A.A., Gilpin D.F., Moriarty T.F., McGrath S.J., et al. Use of culture and molecular analysis to determine the effect of antibiotic treatment on microbial community diversity and abundance during exacerbation in patients with cystic fibrosis. Thorax 2011, 66(7):579-584.
14. Sibley C.D., Grinwis M.E., Field T.R., Eshaghurshan C.S., Faria M.M., Dowd S.E., et al. Culture enriched molecular profiling of the cystic fibrosis airway microbiome. PLoS One 2011, 6(7):e22702.
15. UK Cystic Fibrosis Trust Microbiology Laboratory Standards Working Group Laboratory standards for processing microbiological samples from people with cystic fibrosis 2010.
16. Hauser A.R., Jain M., Bar-Meir M., McColley S.A. Clinical significance of microbial infection and adaptation in cystic fibrosis. Clin Microbiol Rev 2011, 24(1):29-70.
17. Rogers G.B., Hart C.A., Mason J.R., Hughes M., Walshaw M.J., Bruce K.D. Bacterial diversity in cases of lung infection in cystic fibrosis patients: 16S ribosomal DNA (rDNA) length heterogeneity PCR and 16S rDNA terminal restriction fragment length polymorphism profiling. J Clin Microbiol 2003, 41(8):3548-3558.
18. Cox M., Allgaier M., Taylor B., Baek M., Huang Y., Daly R., et al. Airway microbiota and pathogen abundance in age-stratified cystic fibrosis patients. PLoS One 2010, 5(6):e11044.
19. Harris J.K., De Groote M.A., Sagel S.D., Zemanick E.T., Kapsner R., Penvari C., et al. Molecular identification of bacteria in bronchoalveolar lavage fluid from children with cystic fibrosis. Proc Natl Acad Sci USA 2007, 104(51):20529-20533.
20. Guss A.M., Roeselers G., Newton I.L., Young C.R., Klepac-Ceraj V., Lory S., et al. Phylogenetic and metabolic diversity of bacteria associated with cystic fibrosis. ISME J 2011, 5(1):20-29.
21. van der Gast C.J., Walker A.W., Stressmann F.A., Rogers G.B., Scott P., Daniels T.W., et al. Partitioning core and satellite taxa from within cystic fibrosis lung bacterial communities. ISME J 2011, 5:780-791.
22. Zhao J., Schloss P.D., Kalikin L.M., Carmody L.A., Foster B.K., Petrosino J.F., et al. Decade-long bacterial community dynamics in cystic fibrosis airways. Proc Natl Acad Sci U S A 2012, 109(15):5809-5814.
23. Filkins L.M., Hampton T.H., Gifford A.H., Gross M.J., Hogan D.A., Sogin M.L., et al. The prevalence of Streptococci and increased polymicrobial diversity associated with cystic fibrosis patient stability. J Bacteriol 2012, 194(17):4709-4717.
24. Fodor A.A., Klem E.R., Gilpin D.F., Elborn J.S., Boucher R.C., Tunney M.M., et al. The adult cystic fibrosis airway microbiota is stable over time and infection type, and highly resilient to antibiotic treatment of exacerbations. PLoS One 2012, 7(9):e45001.
25. Delhaes L., Monchy S., Fréalle E., Hubans C., Salleron J., Leroy S., et al. The arway microbiota in cystic fibrosis: a complex fungal and bacterial community - implications for therapeutic management. PLoS One 2012, 7(4):e36313.
26. Stressmann F.A., Rogers G.B., van der Gast C.J., Marsh P., Vermeer L.S., Carroll M.P., et al. Long-term cultivation-independent microbial diversity analysis demonstrates that bacterial communities infecting the adult cystic fibrosis lung show stability and resilience. Thorax 2012, 67(10):867-873. [Oct].
27. Ulrich M., Beer I., Braitmaier P., Dierkes M., Kummer F., Krismer B., et al. Relative contribution of Prevotella intermedia and Pseudomonas aeruginosa to lung pathology in airways of patients with cystic fibrosis. Thorax 2010 November 01, 65(11):978-984.
28. Daniels T.W., Rogers G.B., Stressmann F.A., van der Gast C.J., Bruce K.D., Jones G.R., et al. Impact of antibiotic treatment for pulmonary exacerbations on bacterial diversity in cystic fibrosis. J Cyst Fibros 2013, 12(1):22-28. [Jan].
29. Taccetti G., Bianchini E., Cariani L., Buzzetti R., Costantini D., Trevisan F., et al. Early antibiotic treatment for Pseudomonas aeruginosa eradication in patients with cystic fibrosis: a randomised multicentre study comparing two different protocols. Thorax 2012 October 01, 67(10):853-859.
30. Denton M., Todd N.J., Littlewood J.M. Role of anti-pseudomonal antibiotics in the emergence of Stenotrophomonas maltophilia in cystic fibrosis patients. Eur J Clin Microbiol Infect Dis 1996, 15(5):402-405.
31. Griffith D.E., Aksamit T., Brown-Elliott B.A., Catanzaro A., Daley C., Gordin F., et al. An official ATS/IDSA statement: diagnosis, treatment, and prevention of nontuberculous mycobacterial diseases. Am J Respir Crit Care Med 2007, 175(4):367-416.
32. Ryan R.P., McCarthy Y., Watt S.A., Niehaus K., Dow J.M. Intraspecies signaling involving the diffusible signal factor BDSF (cis-2-dodecenoic acid) influences virulence in Burkholderia cenocepacia. J Bacteriol 2009, 191(15):5013-5019.
33. Twomey K.B., O'Connell O.J., McCarthy Y., Dow J.M., O'Toole G.A., Plant B.J., et al. Bacterial cis-2-unsaturated fatty acids found in the cystic fibrosis airway modulate virulence and persistence of Pseudomonas aeruginosa. ISME J 2012, 6(5):939-950.
34. Sibley C.D., Duan K., Fischer C., Parkins M.D., Storey D.G., Rabin H.R., et al. Discerning the complexity of community interactions using a Drosophila model of polymicrobial infections. PLoS Pathog 2008, 4(10):e1000184.
35. Sibley C.D., Parkins M.D., Rabin H.R., Duan K., Norgaard J.C., Surette M.G. A polymicrobial perspective of pulmonary infections exposes an enigmatic pathogen in cystic fibrosis patients. Proc Natl Acad Sci USA 2008, 105(39):15070-15075.
36. Hogardt M., Ulrich J., Riehn-Kopp H., Tümmler B. EuroCareCF quality assessment of diagnostic microbiology of cystic fibrosis isolates. J Clin Microbiol 2009, 47(11):3435-3438.
37. Bosshard P.P., Zbinden R., Abels S., Böddinghaus B., Altwegg M., Böttger E.C. 16S rRNA gene sequencing versus the API 20 NE system and the VITEK 2 ID-GNB card for identification of nonfermenting gram-negative bacteria in the clinical laboratory. J Clin Microbiol April 2006, 44(4):1359-1366.
38. Wellinghausen N., Köthe J., Wirths B., Sigge A., Poppert S. Superiority of molecular techniques for identification of gram-negative, oxidase-positive rods, including morphologically nontypical Pseudomonas aeruginosa, from patients with cystic fibrosis. J Clin Microbiol August 2005, 43(8):4070-4075.
39. Ghegan M.D., Wise S.K., White D.R., Flume P.A., Bowman C.M., Virella-Lowell I., et al. Cost-effective airway cultures in the cystic fibrosis patient. Am J Otolaryngol 2009, 30(3):150-152.
40. Worlitzsch D., Rintelen C., Böhm K., Wollschläger B., Merkel N., Borneff-Lipp M., et al. Antibiotic-resistant obligate anaerobes during exacerbations of cystic fibrosis patients. Clin Microbiol Infect 2009, 15(5):454-460.
41. Borman A.M., Palmer M.D., Delhaes L., Carrère J., Favennec L., Ranque S., et al. Lack of standardization in the procedures for mycological examination of sputum samples from CF patients: a possible cause for variations in the prevalence of filamentous fungi. Med Mycol 2010, 48(1):S88-S97.
42. Shreve M.R., Butler S., Kaplowitz H.J., Rabin H.R., Stokes D., Light M., et al. Impact of microbiology practice on cumulative prevalence of respiratory tract bacteria in patients with cystic fibrosis. J Clin Microbiol 1999, 37(3):753-757.
43. Asner S., Waters V., Solomon M., Yau Y., Richardson S.E., Grasemann H., et al. Role of respiratory viruses in pulmonary exacerbations in children with cystic fibrosis. J Cyst Fibros 2012, 11(5):433-439. [Sep].
44. Bittar F., Richet H., Dubus J., Reynaud-Gaubert M., Stremler N., Sarles J., et al. Molecular detection of multiple emerging pathogens in sputa from cystic fibrosis patients. PLoS One 2008, 3(8):e2908.
45. Marko D.C., Saffert R.T., Cunningham S.A., Hyman J., Walsh J., Arbefeville S., et al. Evaluation of the Bruker Biotyper and Vitek MS Matrix-Assisted Laser Desorption Ionization-Time of Flight Mass Spectrometry systems for identification of nonfermenting Gram-negative bacilli isolated from cultures from cystic fibrosis patients. J Clin Microbiol 2012, 50(6):2034-2039.
46. Desai A.P., Stanley T., Atuan M., McKey J., Lipuma J.J., Rogers B., et al. Use of matrix assisted laser desorption ionisation-time of flight mass spectrometry in a paediatric clinical laboratory for identification of bacteria commonly isolated from cystic fibrosis patients. J Clin Pathol 2012, 65(9):835-838.
47. Vanlaere E., Sergeant K., Dawyndt P., Kallow W., Erhard M., Sutton H., et al. Matrix-assisted laser desorption ionisation-time-of of-flight mass spectrometry of intact cells allows rapid identification of Burkholderia cepacia complex. J Microbiol Methods 2008, 75(2):279-286. [10].
48. Miñán A., Bosch A., Lasch P., Stämmler M., Serra D.O., Degrossi J., et al. Rapid identification of Burkholderia cepacia complex species including strains of the novel Taxon K, recovered from cystic fibrosis patients by intact cell MALDI-ToF mass spectrometry. Analyst 2009, 134(6):1138-1148.
49. Check W. Infectious disease meets mass spectrometry Available at, [Accessed May 2012, 2012]. http://www.cap.org/apps/cap.portal.
50. Gaillot O., Blondiaux N., Loïez C., Wallet F., Lemaître N., Herwegh S., et al. Cost-effectiveness of switch to matrix-assisted desorption ionization-time of flight mass spectrometry for routine bacterial identification. J Clin Microbiol 2011, 49(12):4412.
51. Smith A.L., Fiel S.B., Mayer-Hamblett N., Ramsey B., Burns J.L. Susceptibility testing of Pseudomonas aeruginosa isolates and clinical response to parenteral antibiotic administration: lack of association in cystic fibrosis. Chest 2003, 123(5):1495-1502.
52. Hurley M.N., Ariff A.H., Bertenshaw C., Bhatt J., Smyth A.R. Results of antibiotic susceptibility testing do not influence clinical outcome in children with cystic fibrosis. J Cyst Fibros 2012, 11(4):288-292.
53. Parkins M.D., Rendall J.C., Elborn J.S. Incidence and risk factors for pulmonary exacerbation treatment failures in patients with cystic fibrosis chronically infected with Pseudomonas aeruginosa. Chest 2012, 141(2):485-493.
54. Foweraker J.E., Laughton C.R., Brown D.F.J., Bilton D. Phenotypic variability of Pseudomonas aeruginosa in sputa from patients with acute infective exacerbation of cystic fibrosis and its impact on the validity of antimicrobial susceptibility testing. J Antimicrob Chemother 2005, 55(6):921-927.
55. Kirchner S., Fothergill J.L., Wright E.A., James C.E., Mowat E., Winstanley C. Use of artificial sputum medium to test antibiotic efficacy against Pseudomonas aeruginosa in conditions more relevant to the cystic fibrosis lung. J Vis Exp 2012, 64:e3857.
56. Moskowitz S.M., Emerson J.C., McNamara S., Shell R.D., Orenstein D.M., Rosenbluth D., et al. Randomized trial of biofilm testing to select antibiotics for cystic fibrosis airway infection. Pediatr Pulmonol 2011, 46(2):184-192.
57. Hill D., Rose B., Pajkos A., Robinson M., Bye P., Bell S., et al. Antibiotic susceptibilities of Pseudomonas aeruginosa isolates derived from patients with cystic fibrosis under aerobic, anaerobic, and biofilm conditions. J Clin Microbiol 2005, 43(10):5085-5090.
58. Serisier D.J., Tuck A., Matley D., Carroll M.P., Jones G. Antimicrobial susceptibility and synergy studies of cystic fibrosis sputum by direct sputum sensitivity testing. Eur J Clin Microbiol Infect Dis 2012, 31(11):3211-3216. [Nov].
59. Aaron S.D., Vandemheen K.L., Ferris W., Fergusson D., Tullis E., Haase D., et al. Combination antibiotic susceptibility testing to treat exacerbations of cystic fibrosis associated with multiresistant bacteria: a randomised, double-blind, controlled clinical trial. Lancet 2005, 366(9484):463-471. [8/6-12].
60. Lang B., Aaron S., Ferris W., Hebert P., MacDonald N. Multiple combination bactericidal antibiotic testing for patients with cystic fibrosis infected with multiresistant strains of Pseudomonas aeruginosa. Am J Respir Crit Care Med 2000, 162(6):2241-2245.
61. Moskowitz S.M., Foster J.M., Emerson J., Burns J.L. Clinically feasible biofilm susceptibility assay for isolates of Pseudomonas aeruginosa from patients with cystic fibrosis. J Clin Microbiol 2004, 42(5):1915-1922.
62. Moskowitz S.M., Foster J.M., Emerson J.C., Gibson R.L., Burns J.L. Use of Pseudomonas biofilm susceptibilities to assign simulated antibiotic regimens for cystic fibrosis airway infection. J Antimicrob Chemother 2005, 56(5):879-886.
63. Keays T., Ferris W., Vandemheen K.L., Chan F., Yeung S.W., Mah T.F., et al. A retrospective analysis of biofilm antibiotic susceptibility testing: a better predictor of clinical response in cystic fibrosis exacerbations. J Cyst Fibros 2009, 8(2):122-127.
64. Holland C.A. Publications & Resources: FDA-cleared/approved molecular diagnostics tests Available at, [Accessed Aug 13, 2012]. http://www.amp.org/.
65. Peeling R.W., Smith G., Bossuyt P.M. A guide for diagnostic evaluations. Nat Rev Microbiol 2010, 8(12 Suppl):S2-S6.
66. Compton J. Nucleic acid sequence-based amplification. Nature 1991, 350(6313):91-92.
67. Mori Y., Notomi T. Loop-mediatedisothermalamplification(LAMP): arapid, accurate, andcost-effective diagnostic method for infectious diseases. J Infect Chemother 2009, 15(2):62-69.
68. Harkins A.L., Munson E. Molecular diagnosis of sexually transmitted Chlamydia trachomatis in the United States. ISRN Obstet Gynecol 2011, 2011:279149.
69. Rogers G.B., Bruce K.D. Next-generation sequencing in the analysis of human microbiota: essential considerations for clinical application. Mol Diagn Ther 2010, 14(6):343-350.
70. Deschaght P., Van daele S., De Baets F., Vaneechoutte M. PCR and the detection of Pseudomonas aeruginosa in respiratory samples of CF patients. A literature review. J Cyst Fibros 2011, 0(5):293-297. [9].
71. Seegene to unveil breakthrough technology for highly multiplexed quantitative real-time molecular assays at AACC 2012 Available at, [Accessed Aug 15, 2012]. http://www.seegene.com/en/news/press_view.php?idx=303&view_cur_page=1.
72. Waters V., Ratjen F. Standard versus biofilm antimicrobial susceptibility testing to guide antibiotic therapy in cystic fibrosis. Cochrane Database Syst Rev 2012, [(12): Art. No.: CD009528].
73. Strateva T., Yordanov D. Pseudomonas aeruginosa - a phenomenon of bacterial resistance. J Med Microbiol 2009, 58(9):1133-1148.
74. Breidenstein E.B.M., de la Fuente-Núñez C., Hancock R.E.W. Pseudomonas aeruginosa: all roads lead to resistance. Trends Microbiol 2011, 19(8):419-426. [8].
75. Beuving J., Verbon A., Gronthoud F.A., Stobberingh E.E., Wolffs P.F.G. Antibiotic susceptibility testing of grown blood cultures by combining culture and real-time polymerase chain reaction is rapid and effective. PLoS One 2011, 6(12):e27689.
76. Waldeisen J.R., Wang T., Mitra D., Lee L.P. A real-time PCR antibiogram for drug-resistant sepsis. PLoS One 2011, 6(12):e28528.
77. Hansen W.L., Beuving J., Verbon A., Wolffs P.F. One-day workflow scheme for bacterial pathogen detection and antimicrobial resistance testing from blood cultures. J Vis Exp 2012, 65:e3254.
78. Weigel L.M., Sue D., Michel P.A., Kitchel B., Pillai S.P. A rapid antimicrobial susceptibility test for Bacillus anthracis. Antimicrob Agents Chemother 2010, 54(7):2793-2800.
79. Rolain J.M., Mallet M.N., Fournier P.E., Raoult D. Real-time PCR for universal antibiotic susceptibility testing. J Antimicrob Chemother 2004 August 01, 54(2):538-541.
80. Schadt E.E., Turner S., Kasarskis A. A window into third-generation sequencing. Hum Mol Genet 2010, 19(R2):R227-R240.
81. Loman N.J., Misra R.V., Dallman T.J., Constantinidou C., Gharbia S.E., Pallen M.J. Performance comparison of benchtop high-throughput sequencing platforms. Nat Biotechnol 2012, 30(5):434-439.
82. Bittar F., Rolain J.M. Detection and accurate identification of new or emerging bacteria in cystic fibrosis patients. Clin Microbiol Infect 2010, 16(7):809-820.
83. Abbott's PLEX-ID molecular system and tests for broad microbial identification obtain CE marking Available at, [Accessed May 23, 2012]. http://www.abbott.com/news-media/press-releases/abbotts-plexid-molecular-system-and-tests-for-broad-microbial-identification-obtain-ce-marking.htm.
84. Palacios G., Hornig M., Cisterna D., Savji N., Bussetti A.V., Kapoor V., et al. Streptococcus pneumoniae coinfection is correlated with the severity of H1N1 pandemic influenza. PLoS One 2009, 4(12):e8540.